linjc16/ctgov huggingface dataset:
Vibration Therapy Effects on Muscle Firing Patterns

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the effects of whole body vibration therapy on muscle firing patterns as measured by EMG analysis.

Detailed Description
-----------------
Proprioception is the specialized sensory modality that informs the body as to movement, position, and spatial orientation through mechanisms that track sensations accompanying joint movement and position. Mechanoreceptors in joints, along with vestibular, visual, muscle spindle, Golgi tendon organ, ligament and tendon sensory receptors, comprise the propriosensory system, which conveys information to the motor system to maintain equilibrium on a reflexive, automatic basis. Alterations in somatosensory input from mechanoreceptors have been identified as causing aberrant muscle firing patterns.

Official Title
-----------------
Vibration Therapy Effects on Muscle Firing Patterns

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Device: Whole Body Vibration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Logan student, staff, or faculty with no history of ankle injury Ages 18 - 60 years old Logan student, staff, or faculty with no history of ankle surgery No visual or vestibular condition that would affect balance Exclusion Criteria: Systemic illnesses that have an adverse effect on balance Local infection, injury, or other malignancy affecting the lower extremity Any unstable joints of the lower extremity Any spinal manipulation within 48 hours Prescription or herbal muscle stimulants, relaxants, etc. that could affect balance Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Whole Body Vibration|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Electromyographic analysis of the gastrocnemius muscle |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
whole body vibration, muscle physiology
Septic Pseudarthrosis Of Long Bone : Experience In A Regional Reference Center

Study Overview
=================
Brief Summary
-----------------
Description of septic pseudarthrosis with chirurgical treatment in two steps (first step : Implementation of cement, second step : bone reconstruction, with or without device)

Official Title
-----------------
Septic Pseudarthrosis Of Long Bone : Experience In A Regional Reference Center

Conditions
-----------------
Pseudoarthrosis of Bone

Intervention / Treatment
-----------------
* Other: Description of treatment of septic pseudarthrosis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients having septic pseudarthrosis of long bone treated at the CRIOAc LYON Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Description of treatment of septic pseudarthrosis<br>chirurgical and medical treatment | Other: Description of treatment of septic pseudarthrosis<br>* description of chirurgical 2 steps management of septic pseudarthrosis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Description of treatment of septic pseudarthrosis : chirurgical treatment - rate of use of this type of chirurgical treatment among patients with septic pseudarthrosis | Description of treatment of septic pseudarthrosis : chirurgical treatment | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Description of treatment of septic pseudarthrosis : medical treatment - duration of treatment in patients having sepstic pseudarthrosis | Description of treatment of septic pseudarthrosis : medical treatment | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) | 
| Treatment failure : rate of failure with this 2 times chirurgical treatment | Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) |
Home Ventilatory Support in Children

Study Overview
=================
Brief Summary
-----------------
The study consist of children, who have used home ventilatory support during years 2010-2020 in Tampere University Hospital. The study will describe retrospectively different diagnoses and symptoms which will lead to home ventilatory support. We also study compliance to treatment and it's disanvantages. The prospective part of the study describes the quality of live of these children by using questionnaires (PedSQL).

Official Title
-----------------
Home Ventilatory Support in Children

Conditions
-----------------
Sleep Apnea Syndromes in Children

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - ICD-10 Code for Sleep apnea diagnose G47.3 AND G47.3 diagnose found from pediatric electronic patient records between years 2010-2020 OR Patient name found from pediatric multidisciplinary home respiratory team's clinical list Exclusion Criteria: Age over 16 Patient starting home ventilation after 31st December 2020 or treatment ending before 1st January 2010 patients with sleep apnea but without home respiratory support treatment Only theophylline treatment High-flow oxygen therapy Age over 16 at treatment onset Never started treatment Treatment starting point and ending before year 2010

Ages Eligible for Study
-----------------
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient demographics of patients from 0 up to 16 years old treated by a multidisciplinary home respiratory support-team during January 2010 to December 2020 in Tampere University Hospital, Finland | Data included patient demographics | 2022-2023 | 
| Number of patients with clinical characteristics | Data included underlying medical conditions and medications. The circumstances for home respiratory support onset, frequency of follow-up, complications, operative interventions to treat sleep apnea before and during period with home respiratory support were collected. The type of respiratory support (device, mode, interface) was recorded. | 2022-2023 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The duration of treatment | The duration of treatment during January 2010 to December 2020 in Tampere University Hospital, Finland were collected. | 2022-2023 |
Short-Term Preoperative Traction Method for Rigid and Severe Scoliosis

Study Overview
=================
Brief Summary
-----------------
The investigators collected retrospective data of severe (>80o) and rigid scoliosis patients who underwent preoperative traction before correction surgery from 2016 to 2018. The first group consisted of patients who underwent Cotrel traction exercises and second group underwent continuous-progressively increasing Skull Tongs Femoral Traction (STFT) traction. Posterior fusion was performed in all patients. Intraoperative parameters (blood loss, operation time and level instrumented) and radiologic change (initial, post-traction and postoperative Cobb Angle) was evaluated and analyzed

Official Title
-----------------
Short-Term Preoperative Traction Method for Rigid and Severe Scoliosis: A Comparison Between Skull Tongs-Femoral Traction and Cotrel Longitudinal Traction

Conditions
-----------------
Scoliosis Idiopathic

Intervention / Treatment
-----------------
* Procedure: Preoperative traction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adolescence/adult idiopathic scoliosis; severe and rigid scoliosis (defined as Cobb angle more than 80° and flexibility index less than 25%); either skull tongs-femoral traction or Cotrel longitudinal traction used in the preoperative time period Exclusion Criteria: other types of scoliosis (neuromuscular scoliosis, congenital scoliosis, etc.) intradural abnormalities (diastomatomyelia, tethered cord, etc) history of previous spine surgery

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Skull tong femoral traction<br> | Procedure: Preoperative traction<br>* Compare two methods of preoperative traction (Cotrel traction exercises and skull tongs femoral traction)<br>|
| Cotrell longitudinal traction<br> | Procedure: Preoperative traction<br>* Compare two methods of preoperative traction (Cotrel traction exercises and skull tongs femoral traction)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Radiologic change | Preoperative, post traction and postoperative xray | - Baseline - Immediately after 2 weeks of preoperative traction - immediately after the correction surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood loss | The amount of blood loss during the correction surgery | Intraoperative | 
| Duration of surgery | The time required to perform the correction surgery | Intraoperative | 
| Number of instrumented levels | the number of vertebrae instrumented during the correction surgery | Intraoperative |
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia

Study Overview
=================
Brief Summary
-----------------
This study is being done to evaluate the long-term safety of tegaserod in women with symptoms of dyspepsia who have completed the core study. Tegaserod will be evaluated at 6 mg twice daily.

Official Title
-----------------
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia

Conditions
-----------------
Dyspepsia

Intervention / Treatment
-----------------
* Drug: Tegaserod


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female, 18 years and older Fulfilled eligibility criteria in CHTF919 D2302 (double blind study) and successfully completed the double-blind study Exclusion Criteria: - Early discontinuation from the double-blind study Other protocol-defined inclusion/exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Tegaserod|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Long term safety at 6 months. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Long term safety at 1 year. |  |  | 
| Quality of life : Nepean Dyspepsia Index, WPAI, patient perception of study medication-dyspepsia questionnaire. |  |  | 
| Efficacy on satisfactory relief at month 6 and 12. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dyspepsia, gastrointestinal, tegaserod
Safety Study of Tivanisiran to Treat Dry Eye

Study Overview
=================
Brief Summary
-----------------
This study will examine the safety of tivanisiran sodium eye drops versus vehicle when dosed once daily for 1 year in subjects with signs and symptoms of dry eye disease (DED).

Official Title
-----------------
Safety Study of Tivanisiran to Treat Dry Eye

Conditions
-----------------
Dry Eye Disease

Intervention / Treatment
-----------------
* Drug: Tivanisiran sodium ophthalmic solution
* Drug: Vehicle ophthalmic solution


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Be at least 18 years of age Have given their written consent to participate in the study Use of artificial tears (AT), autologous serum or specific dry eye medications during the last 6 months prior to the selection Exclusion Criteria: Pregnant or breast feeding females with a postitive pregnancy test Women of childbearing potential not willing to use a medically acceptable contraceptive method Currently participating or has participated in another clinical trial within the 2 months prior to inclusion Current, previous chronic or recurrent medical condition that, according to the investigator, might impact on the study Any concomitant treatment or prior ocular procedure or surgery in either eye or alteration of the dose of systemic medications that could interfere in the trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Tivanisiran sodium ophthalmic solution<br> | Drug: Tivanisiran sodium ophthalmic solution<br>* 1 drop in the affected eye(s) once daily<br>|
| Placebo Comparator: Vehicle ophthalmic solution<br> | Drug: Vehicle ophthalmic solution<br>* 1 drop in the affected eye(s) once daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency and percentage of subjects with ocular and non-ocular treatment emergent adverse events (TEAEs) for 1 year |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
siRNA, oligonucleotide, keratoconjunctivitis sicca, SYL1001
Safety and Efficacy of an Investigational Multi-Purpose Disinfecting Solution

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if Alcon MPDS is safe and effective for silicone hydrogel and soft hydrogel contact lens wearers.

Detailed Description
-----------------
The purpose of this study is to determine if Alcon Multi-Purpose Disinfecting Solution (MPDS) is safe and effective for silicone hydrogel and soft hydrogel contact lens wearers.

Official Title
-----------------
Safety and Efficacy of an Investigational Multi-Purpose Disinfecting Solution (MPDS)

Conditions
-----------------
Healthy Contact Lens Wearers

Intervention / Treatment
-----------------
* Device: Alcon MPDS
* Device: ReNu Fresh MPS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Silicone hydrogel or soft contact lens wearers who wear their lenses daily wear (i.e. disinfect lenses every night). Patient must be able to read. Vision correctable to 20/30 or better with contact lenses. Exclusion Criteria: Sensitivity to multi-purpose solutions. Using any topical ocular OTC or prescribed topical ocular medications. History or current ocular infections or ocular inflammatory events. Ocular surgery within the past year. With a medical condition or using medications that cause ocular side effects. Participation in any investigational study within the past 30 days.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Alcon MPDS<br>Alcon Multi-Purpose Disinfecting Solution (MPDS) | Device: Alcon MPDS<br>* Multi-Purpose Solution intended for use with silicone hydrogel and soft contact lenses<br>* Other names: Alcon Multi-Purpose Disinfecting Solution (MPDS);|
| Active Comparator: ReNu Fresh Multi-Purpose Solution<br>ReNu Fresh Multi-Purpose Solution | Device: ReNu Fresh MPS<br>* ReNu Fresh MPS is a marketed product indicated for cleaning, removing protein deposits, rinsing, disinfecting and storage of soft contact lenses.<br>* Other names: ReNu Fresh Multi-Purpose Solution (MPS);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subjective Acceptance | Lens Moisture Subject Rated Likert Item (1-Strongly Agree to 5-Strongly Disagree) | Day 90 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Contact Lenses, Contact Lens Care, Multi-Purpose Solution
Sialendoscopy in Treatment of Submandibular Gland Sialolithiasis

Study Overview
=================
Brief Summary
-----------------
Salivary disorders are common reason for ENT specialist consultation. Sialolithiasis are the most frequent salivary obstruction disease and are characterized by the development of calcified structures in the salivary gland, especially in the submandibular gland. The management of salivary obstruction has changed over the past 30 years. Sialendoscopy is considered as a minimally invasive procedure that allows endoscopic visualization of the salivary ductal system and is increasingly used in both diagnosis and treatment. Moreover, many studies have shown the effectiveness of this procedure. Classification of lithiasis has been set up in 2008 to standardize the nomenclature and was used for patient care since 2009. The main objective of this study is to evaluate the relevance of the lithiasis's classification to predict the efficacy of sialendoscopy in treatment of sialolithiases.

Official Title
-----------------
Predictive Value of the Sialendoscopy in Treatment of Submandibular Gland Sialolithiasis: a Retrospective Study

Conditions
-----------------
Lithiasis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patient Patient treated in CHR Metz-Thionville between 2013 and 2020 With a pathological impairment (suspected or confirmed) of a salivary gland With sialendoscopy indication for diagnosis and/or treatment Exclusion Criteria: Opposed to use data Without sialendoscopy indication Without lithiasis salivary gland disorder With parotid gland lithiasis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrence of symptom | Absence or presence of symptoms associated to lithiasis | Month 6 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of clinical signs | number of clinical signs of the clinical suspicion | Day 1 | 
| Number of intraoperative complications | number of intraoperative complications | Day 1 | 
| Number of post-operative complications | Number of post-operative complications | Day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
submandibular gland, classification, sialendoscopy
Transvaginal Treatment of Symptomatic Cystocele Grade II-III

Study Overview
=================
Brief Summary
-----------------
This observational study will evaluate treatment of symptomatic cystocele grade II-III with Cousin Biomesh and Allium Medical Endofast Reliant. Data about 100 patients will be collected. Follow-up till 3 years after the procedure. Primary endpoint is absence of recurrence.

Official Title
-----------------
Transvaginal Treatment of Symptomatic Cystocele Grade II-III Using Cousin Biomesh Soft Prolaps or Allium Medical Endofast Reliant

Conditions
-----------------
Cystocele

Intervention / Treatment
-----------------
* Device: cystocele repair with biomesh soft prolaps and endofast reliant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is a woman Patient is between 40 and 90 years old Patient has to sign the informed consent form prior to the procedure Patient has to agree with the scheduled follow-up visits on month 1, month 6, year 1, year 2 and year 3 Patient has symptomatic anterior prolapse Exclusion Criteria: Recurrence cystocele Patient is pregnant Patient has a wish to become pregnant Patient is taking Plavix, Sintrom, Marcoumar, Marevan, Brilique, Efient, Ticlid, Xarelto, Eliquis or Pradaxa. If intake is stopped prior to procedure, patient is allowed to be included. Patient is taking LMWH in a dose of more than 40 mg/day Patient has a life expectancy < 1 year Patient has a known connective tissue disease Patient has a history of surgery of the anterior vaginal wall or pelvis A scheduled hysterectomy during the index-procedure

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: cystocele repair with biomesh soft prolaps and endofast reliant|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Absence of recurrence |  | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Technical success | Correct positioning of the mesh as intended by the surgeon | day 1 | 
| Procedural success | Technical success without complications till 30 days after the index-procedure | 30 days | 
| Peroperative complications | Perforation bowels, bladder or arteries | day 1 | 
| Postoperative complications | Infection, bleeding, recurrence, mesh erosion, pain during sexual activities, pain, discomfort | 3 years | 
| Quality of life | PFDI-20, PFIQ-7, PISQ-12 | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Anterior prolapse